A phase II study assessing the intracranial response to nivolumab and nivolumab combined with ipilimumab in patients with melanoma brain metastases
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- Acronyms ABC Trial
- 28 Aug 2017 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
- 28 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.
- 06 Jun 2017 Results (n=66) assessing antitumour activity and safety, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology